This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Top Morningstar M&A Stock Picks for 2012

Icon Plc

Dublin-based contract research firm Icon Plc (ICLR - Get Report) is a leveraged buyout target like U.S. competitor Charles River Laboratories because of its modest leverage and depressed trading prices, according to Morningstar. The company trades as an ADR on Nasdaq and specializes in outsourced biotech, pharmaceutical and medical device phase I to IV research projects. In 2011, Icon shares dropped over 20% on a slowing of demand in its key European market, according the Morningstar.

Presently, Icon generates more than 40% of its revenue from Europe. "Icon doesn't have the operational baggage of Charles River, but the stock nonetheless has been trading at depressed levels for quite some time now." Writes Morningstar, who points to larger contract research companies like

Covance (CVD) and Quintiles as acquirers who could benefit from Icon's businesses. "Its global infrastructure could make the firm an attractive target for a mid-tier competitor looking to build scale to gain entry into the industry's top ranks."

Morningstar gives Icon Plc a five star rating and a fair value of $32 a share, nearly double its current share price of $18.51. The company is expected to earn $9 cents a share in its fourth quarter 2011 results due on Feb. 23, according to Zacks consensus estimates. Analysts give the company an estimated price target of $19 a share on 2012 revenue of $1.16 billion and profit of $58.9 million, according to data compiled by Bloomberg. For more on Icon, see 8 health care buys ahead of earnings.

>>To see these stocks in action, visit the 10 Top Morningstar M&A Stock Picks for 2012 portfolio on Stockpickr.

--Written by Antoine Gara in New York
11 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABMD $98.99 -0.27%
CHS $12.41 -2.40%
CRL $78.79 -0.77%
DHX $7.00 -1.40%
ICLR $64.89 -2.80%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs